Odyssey Health Finalizes Global BreastCheck™ Distribution, Securing Near-Term Revenue Path

summarizeSummary

Odyssey Health, Inc. announced the closing of its Master Technology and Sub-license Agreement for exclusive global distribution rights to BreastCheck™, a non-invasive breast abnormality test, positioning the company for near-term revenue generation.

check_boxKey Events

• Global Distribution Rights Secured

  Odyssey Health closed the Master Technology and Sub-license Agreement with NeuRX Health, Inc., granting its subsidiary exclusive worldwide marketing and distribution rights for BreastCheck™, a non-invasive test for breast abnormalities. This finalizes the agreement initially entered into on October 14, 2025.

• Near-Term Revenue Potential

  The agreement positions Odyssey to enter the global breast cancer screening market with BreastCheck™, with commercial sales anticipated to commence in the second half of the year, providing a crucial pathway to revenue for the company.

• Amendment to Payment Terms

  An amendment to the agreement specifies that cash consideration to NeuRX will be 10% of net cash proceeds from equity line draws, increasing to 30% once certain technology and material transfer terms are met. This links the licensing cost directly to the company's financing activities.

• Strategic Shift Towards Commercial Products

  This transaction advances Odyssey's strategic transition towards revenue-generating commercial products, a critical development for a company that recently reported a 'going concern' warning.

auto_awesomeAnalysis

This filing is highly significant for Odyssey Health, especially given its recent "going concern" warning. The successful closing of the BreastCheck™ sub-license agreement provides the company with a clear pathway to commercial sales and recurring revenue, anticipated in the second half of the year. This move directly addresses the company's urgent need for revenue generation and strengthens its product portfolio in the medical device sector. The amendment to the payment terms, linking cash consideration to draws from an equity line of credit, highlights the company's reliance on financing to support this venture, but the overall strategic benefit of securing a revenue-generating product outweighs this. Investors should monitor the actual commercial launch and revenue figures to assess the impact on the company's financial stability.